Inomagen Therapeutics, Inc. Awarded NIH SBIR Grant Providing up to $2.9 million to Advance Disease-Modifying Gene Therapy for Atrial Fibrillation

Positive

AI Analysis

Summary

Inomagen Therapeutics received a NIH SBIR grant of up to $2.9 million to advance a non-viral gene therapy for atrial fibrillation. The funding will support preclinical development and manufacturing activities toward a future Investigational New Drug application.

Outcome Details

NIH SBIR Grant awarded

Importance:4/10

Sentiment:

0.60

gene therapynon-viralNIH fundingSBIR grantatrial fibrillationpreclinicalIND application

Related Companies

$FVNNU

Read the original article

Published by PR Newswire Pharma on September 16, 2026 2:55 PM

Read Original